肝癌标志物的最新研究进展
摘要
应具有高敏感性和特异性，能够反映肿瘤的动态变化，并为治疗决策提供指导。近年来，随着分子生物学技术和液体活检
技术的发展，肝癌肿瘤标志物的研究取得了显著进展，从传统的蛋白质标志物到循环核酸、外泌体等多组学标志物，为肝
癌的精准医疗提供了新的机遇。多组学标志物的应用不仅实现了肝癌分子分型的精细化，更推动了靶向治疗和免疫治疗的
精准选择。
关键词
全文:
PDF参考
[1] Wei Zhang，Di Wu，et al. Development and evaluation
of a nomogram prediction model for invasion and metastasis in
primary liver cancer based on serum CD147 and IL-6 [J].Frontiers
in Oncology，2025，15：1524765.
[2]Chivu-EconomescuM, NeculaL, MateiL, et al. Clinical
app-lications of liquid biopsy in gastric cancer[J]. Front Med
(Lausanne), 2021, 8:749250.
[3]PivaVM, De GrandisMC, ZuinIS, et al. ctDNA as
promising tool for the assessment of minimal residual disease
(MRD) and the need of an adjuvant treatment in gastroesophageal
adenocarcinoma[J]. Updates Surg, 2023, 75(2):305-312.
[4]Felismino, T., Martins, L., Barroso, M. et al. Neutrophil-
to-Lymphocyte Ratio (NLR) as a Predictive Biomarker in
Advanced Hepatocellular Carcinoma Treated with First-Line
Immunotherapy. J Gastrointest Canc 56, 175 (2025).
[5]Zhang T Q, Geng Z J, Zuo M X, et al. Camrelizumab
(a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and
hepatic artery infusion chemotherapy for hepatocellular carcinoma
in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II
study[J]. Signal transduction and targeted therapy, 2023, 8(1): 413.
[6] Kudo M, Ren Z, Guo Y, et al. Transarterial
chemoembolisation combined with lenvatinib plus pembrolizumab
versus dual placebo for unresectable, non-metastatic
hepatocellular carcinoma (LEAP-012): a multicentre, randomised,
double-blind, phase 3 study[J]. The Lancet, 2025, 405(10474):
203-215.
[7] Zhu, Yajing; Zhang，et al. Pan Gene expression profile
of anoikis reveals new subtypes of liver cancer and discovery of
therapeutic targets and biomarkers. Scientific Reports, 2025, Vol
15, Issue 1, p1.
[8] Zhen SH，Cheng M，Tao YB，et al. Deep learning for
accurate diagnosis of liver tumor based on magnetic resonance
imaging and clinical data［J］.Front Oncol，2020，10：680.
[9]Circulating tumour DNA methylation markers for diagnosis
and prognosis of hepatocellular carcinoma[J].Nature Materials,
2017, 16(11):1155.
[10]Ding J, Zou X, et al. ZBED4: A Prognostic Biomarker
and Therapeutic Target in Hepatocellular Carcinoma. J Hepatocell
Carcinoma. 2025;12:1873-1892.
[11] R a n j i t h B a l a k r i s h n a n , R a j a s e k a r a n , e t a l .
Subbarayan,Circulating miR-542-3p as a Prognostic Marker
forHepatocellular Carcinoma: A Systematic Review andMeta-
Analysis. Journal of Cellular and Molecular Medicine. 29, no. 14
(2025): e70748.
[12]Guo, X., Zhao, Z., Zhu, L. et al. The evolving landscape
of biomarkers for systemic therapy in advanced hepatocellular
carcinoma. Biomark Res 13, 60 (2025).
(0 摘要 Views, 0 PDF Downloads)
Refbacks
- 当前没有refback。